Drug Interactions between efgartigimod alfa and TheraCys
This report displays the potential drug interactions for the following 2 drugs:
- efgartigimod alfa
- TheraCys (bcg)
Interactions between your drugs
BCG efgartigimod alfa
Applies to: TheraCys (bcg) and efgartigimod alfa
GENERALLY AVOID: The administration of a live, attenuated virus or bacteria as oncolytic immunotherapy during treatment with a neonatal Fc receptor (FcRn) blocker like efgartigimod alfa or rozanolixizumab has not been evaluated. FcRn blockers can cause a transient reduction in IgG levels. In addition, efgartigimod alfa may decrease white blood cell, lymphocyte, and neutrophil counts. Administration of medications containing live, attenuated virus or bacteria during treatment with FcRn blockers may theoretically increase the risk of disseminated infection due to enhanced replication of virus or bacteria in the presence of diminished immune competence. Increased adverse reactions and decreased or suboptimal therapeutic response to the immunotherapy may also occur.
MANAGEMENT: Until more information is available, it may be advisable to avoid the concomitant use of FcRn blockers with oncolytic immunotherapy such as talimogene laherparepvec and the BCG strain of Mycobacterium bovis.
References
- (2022) "Product Information. Vyvgart (efgartigimod alfa)." argenx US Inc.
- (2023) "Product Information. Vyvgart Hytrulo (efgartigimod alfa-hyaluronidase)." argenx US Inc.
- (2023) "Product Information. Rystiggo (rozanolixizumab)." UCB Pharma Inc
Drug and food interactions
No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.